Jerusalem, Israel, June 20, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster entitled “Modulating Hexokinase 2 (HK2) as a Novel Approach to Target Metabolic Immuno-Oncology” at the 25th Biennial Congress of the European Association for Cancer Research (EACR25) in Amsterdam, 30 June - 03 July 2018. The poster will be presented in poster session "Tumour Immunology", on Monday, 02 July 2018 from 10:05 to 17:15 in Hall 3.
About Vidac Pharma
Vidac is a privately-held clinical-stage oncology-focused biopharmaceutical company developing first-in-class drugs using its breakthrough metabolic immuno-oncology platform technology. Vidac is using its proprietary HEXAGON™ bioinformatics tool to identify patients with cancers that have high HK2 levels, across a variety of tumor types. Vidac’s lead drug, VDA-1102 ointment, is in Phase 2b for treatment of Actinic Keratosis, an early form of cutaneous SCC. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors and hematological malignancies, as monotherapies and in combination.
For more information please visit www.vidacpharma.com.
Contact: Shelly Majar +972-2-5952090